GRP78 and α2-macroglobulin are new promising targets for metastatic castrate-resistant prostate cancer treatment.

Clin Transl Oncol

Division of Hematology/Oncology, Department of Medicine, NYU Lutheran Medical Center, 150 55th Street, Brooklyn, NY, 11220, USA.

Published: November 2015

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12094-015-1324-9DOI Listing

Publication Analysis

Top Keywords

grp78 α2-macroglobulin
4
α2-macroglobulin promising
4
promising targets
4
targets metastatic
4
metastatic castrate-resistant
4
castrate-resistant prostate
4
prostate cancer
4
cancer treatment
4
grp78
1
promising
1

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!